

4<sup>th</sup> September 2023

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Disclosure under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, we hereby notify that Cipla Medpro South Africa (Pty) Ltd., a wholly owned subsidiary of the Company in South Africa has entered into a binding term sheet with Actor Holdings (Pty) Ltd. on 4<sup>th</sup> September 2023 for acquisition of 100% equity stake in Actor Pharma (Pty) Ltd., South Africa.

Details required to be disclosed under the SEBI Listing Regulations, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July 2023 have been provided in Annexure – I to this letter.

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Mandar Kurghode

**Annexure – I**

Details as per circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.	<p>Actor Pharma (Pty) Ltd (“Actor Pharma”) is a registered pharmaceutical company in South Africa.</p> <p>For other details please refer point (j) below.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	<p>The acquisition is not a related party transaction.</p> <p>None of the promoter / promoter group / group companies have any interest in the said transaction.</p>
c)	Industry to which the entity being acquired belongs	Pharmaceutical Industry
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This is a strategic acquisition to unlock the future growth opportunities and leverage cost synergies in South African market.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	This transaction shall require approval of the South African Competition Commission.
f)	Indicative time-period for completion of the acquisition	<p>The proposed acquisition is subject to signing of the share purchase agreement (SPA), which is expected to be signed within 14 days from the date of the binding term sheet or such other date as may be mutually agreed between the parties.</p> <p>The transaction is expected to be completed within 4 months from the date of signing of the SPA or upon satisfaction of closing conditions as agreed in the SPA, whichever is earlier or such other date as may be mutually agreed between the parties, subject to regulatory approval stated in point (e) above.</p>

g)	Nature of consideration - whether cash consideration or share swap and details of the same	Cash
h)	cost of acquisition and/or the price at which the shares are acquired	ZAR 900 million (~USD 48.6 million) subject to customary adjustments.
i)	Percentage of shareholding / control acquired and / or number of shares acquired	Acquisition of 920 equity shares from Actor Holdings (Pty) Ltd. representing 100% of the equity stake in Actor Pharma.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Actor Pharma is a privately owned pharmaceutical company in South Africa that was founded in 2009 and specializes in consumer health and generic medicine.</p> <p>Actor Pharma has established brand equity in consumer driven markets and has a solid pipeline of new launches in niche markets. The acquisition offers Cipla a high mix of over-the-counter revenue and a portfolio that supplements Cipla's strength.</p> <p><b>Turnover:</b>  FY 2023 – ZAR 233.6 million (USD 12.6 million)  FY 2022 – ZAR 199.3 million (USD 10.8 million)  FY 2021 – ZAR 154.4 million (USD 8.3 million)</p>